I-Mab ADR (IMAB): Price and Financial Metrics
IMAB Price/Volume Stats
| Current price | $1.81 | 52-week high | $3.45 |
| Prev. close | $1.80 | 52-week low | $1.16 |
| Day low | $1.80 | Volume | 109,500 |
| Day high | $1.82 | Avg. volume | 460,033 |
| 50-day MA | $1.79 | Dividend yield | N/A |
| 200-day MA | $1.82 | Market Cap | 146.07M |
IMAB Stock Price Chart Interactive Chart >
I-Mab ADR (IMAB) Company Bio
I-Mab, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel or highly differentiated biologics to treat diseases with unmet medical needs, primarily cancers and autoimmune disorders worldwide. It is developing TJ202, a CD38 antibody in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; TJ101, a long-acting human growth hormone that is in Phase II clinical trials to treat pediatric growth hormone deficiency; and TJ301, a IL-6 blocker in Phase II clinical trials for the treatment of ulcerative colitis and other autoimmune diseases. The company's product candidates in Phase I clinical trials include Enoblituzumab, a humanized B7-H3 antibody to treat immuno-oncology; TJ107, a long-acting recombinant human IL-7 to treat cancer treatment-related lymphopenia and cancer immunotherapy; TJC4, a CD47 monoclonal antibody with RBC-sparing differentiation; TJD5, a CD73 antibody for cancer treatment; and TJM2, a GM-CSF monoclonal antibody for rheumatoid arthritis and CAR-T-related therapies. Its product candidates in pre-clinical development comprise TJ210, an antibody targeting myeloid derived suppressor cells in cancers and autoimmune diseases; and TJX7, a novel CXCL13 antibody for autoimmune diseases. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.
Latest IMAB News From Around the Web
Below are the latest news stories about I-MAB that investors may wish to consider to help them evaluate IMAB as an investment opportunity.
Individual investors account for 41% of I-Mab's (NASDAQ:IMAB) ownership, while private equity firms account for 26%Key Insights The considerable ownership by individual investors in I-Mab indicates that they collectively have a... |
I-Mab Announces Participation at Jefferies and Piper Conferences in NovemberI-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies and biologics, today announced its in-person participation in two conferences in November 2023, the Jefferies London Healthcare Conference and the Piper Sandler 35th Annual Healthcare Conference. Details of the conferences and management presentation are as follows: |
Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN)I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies and biologics, and HI-Bio, a clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases (IMDs), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BT |
I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies and biologics, today announced that two poster presentations featuring preclinical data on givastomig (also known as TJ-CD4B/ABL111) and TJ-L14B/ABL503, the Company's 4-1BB-targeting bispecific antibody assets, will be reported at the 38th Society for Immunotherapy o |
I-Mab Announces Phase 1 Data of Givastomig at ESMO 2023I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies and biologics, today announced that the updated clinical results from its Phase 1 study of givastomig (also known as TJ-CD4B/ABL111) in advanced solid tumors will be reported in a poster presentation at the upcoming European Society for Medical Oncology (ESMO) Congre |
IMAB Price Returns
| 1-mo | -1.63% |
| 3-mo | 0.56% |
| 6-mo | 48.36% |
| 1-year | -38.85% |
| 3-year | -97.18% |
| 5-year | N/A |
| YTD | -4.74% |
| 2023 | -54.55% |
| 2022 | -91.18% |
| 2021 | 0.51% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...